Nordic Capital VII and Avista announce the proposed sale of a 19.95% shareholding in ConvaTec to Novo A/S, the investment holding company of the Novo Nordisk Foundation, and a proposed placing of approximately 375 million ordinary shares.
ConvaTec is a leading developer and marketer of innovative medical technologies. With four key business divisions: Advanced Wound Care, Ostomy Care, Continence and Critical Care (CCC) and Infusion Devices, ConvaTec support health care professionals from the hospital to the community health setting. The company has operations in over 100 countries serving consumers and health care professionals on six continents. ConvaTec Group Plc was listed on the London Stock Exchange in October 2016.